High-Risk Merchant Accounts for Peptide Brands: What You Need

TL;DR: Peptide and GLP-1 brands get coded high-risk by every payment processor that touches them, and that's not a mistake to fight — it's a category you plan around. A high-risk merchant account costs more, holds a reserve, and demands clean chargeback numbers, but it's how you actually get paid instead of getting frozen. Your marketing claims affect your processor risk as much as your bank statement does. And whatever happens with payments, the one channel a processor can never touch is the email list you own.

Why peptides read as high-risk to a payment processor

A payment processor doesn't evaluate your product. It evaluates a category, and it does that through an MCC code — the four-digit classification that tells the acquiring bank what kind of business it's underwriting. Research peptides and GLP-1 products land next to nutraceuticals and supplements, a category with a documented history of chargebacks, regulatory scrutiny, and returns. The processor isn't reading your lab certificates. It's pattern-matching against every other peptide seller that came before you, some of whom made disease claims, some of whom got flagged by the FDA, some of whom just ran too many disputes.

Add to that: peptides sit in a gray zone. Research-use-only labeling, ambiguous end-use, and a customer base that sometimes talks about dosing in ways your site never sanctioned. None of that is your fault individually. All of it becomes your risk profile collectively.

What a high-risk merchant account actually is

A standard merchant account assumes low dispute rates and a boring, well-understood product. A high-risk merchant account assumes the opposite, and prices accordingly. You'll pay higher processing fees, sometimes a flat monthly high-risk fee on top, and — this is the one that catches founders off guard — a reserve. A rolling reserve holds back a percentage of each transaction (often 5–10%) for a set window before releasing it to you, so the acquiring bank has a cushion if chargebacks come in later. Some accounts use a flat reserve instead, a fixed dollar amount held for the life of the account.

None of this is punitive. It's the acquiring bank pricing in the risk it's carrying on your behalf.

	Standard Merchant Account	High-Risk Merchant Account
Processing fees	~2.5–3%	3.5–6%+
Reserve	Rare	Common (rolling or flat, 5–10%)
Approval speed	Days	1–3 weeks, more documentation
Chargeback tolerance	Standard (under 1%)	Low — accounts can be terminated at 1–2%
Category fit	Broad	Requires processors who accept your MCC code
Backup processor	Optional	Effectively required

What to expect, and how to qualify

Don't apply pretending you're a standard e-commerce store. Processors who specialize in high-risk categories exist precisely because they can price and underwrite you correctly — and they'll find out your real category anyway, usually after your first statement, which is the fast track to termination. Disclose upfront. Have your business documentation in order: incorporation, bank statements, a clear return policy, and a website that doesn't make claims your product can't back up.

Expect to submit more than a standard applicant would — processing history if you have it, projected volume, and sometimes a personal guarantee. Expect the underwriting conversation to focus on chargebacks before anything else. A processor approving a peptide brand is making a bet that you'll keep disputes low; everything in the application is them trying to price that bet.

How you keep the account you got

Approval is the easy part. Keeping the account is where most brands actually lose ground. Chargebacks are the single biggest lever — cross roughly 1–2% and you risk landing in a chargeback monitoring program, or losing the account outright. Keep your billing descriptor recognizable, make refunds easy enough that customers use them instead of disputing, and respond to every chargeback with evidence, every time.

Then build redundancy. Being dropped by a processor that didn't fully understand your category is common enough in this space that it shouldn't surprise you — sometimes a processor changes its risk appetite overnight and re-underwrites its whole book, and peptide brands are first to go. A backup processor isn't optional caution. It's the plan for a day you should assume is coming.

The link between your marketing claims and your processor risk

Processors read your website the same way regulators do. A page implying your peptide treats a condition, reverses aging, or replaces a prescription drug isn't just an FDA problem under 21 CFR 201.128 — it's a chargeback magnet and a reason for a processor to flag your account on review. Customers who buy on the promise of a disease claim and don't get the result they expected are exactly the customers who file disputes. Research-only framing isn't just the compliant way to write about semaglutide or any research peptide — it's the version of your marketing that keeps your processor relationship intact too. The two risks are the same risk wearing different clothes.

This is where most peptide brands underestimate the connection. Legal risk and payment risk aren't parallel tracks — they're the same reviewer, twice.

Why email is the channel that survives a processor problem

Here's the part founders in this category learn the hard way: a frozen merchant account is a cash-flow problem, but a frozen or shut-down email platform is a customer problem, and it's often self-inflicted. Klaviyo and Mailchimp have both dropped peptide and GLP-1 brands with little warning, and when that happens you don't just lose your next campaign — you can lose the list itself, mid-relationship, with no export window.

Your merchant account can get re-underwritten, held in reserve, or paused for review, and that's survivable if you have a way to reach your customers directly. That's the entire argument for owning your list on infrastructure that isn't going to decide your category is more trouble than it's worth. We build email marketing for peptide brands exclusively on self-hosted FluentCRM or Sendlane — never Klaviyo, never Mailchimp — because peptide brands need a platform that won't cut them off the way processors sometimes do.

We've taken peptide and GLP-1 brands from startup to 7 and 8 figures, and we only work in this category, so we've watched the payment side and the email side collide often enough to know they need to be handled together. If your merchant account situation is the thing keeping you up, get that solved with a specialist. If your email is still sitting on borrowed platform real estate, that's the piece you actually control — and it's where our done-for-you email service starts.